|
Patent landscape, scope, and claims summary: |
Executive summary
US Patent 10,149,904 is a method-of-treatment patent for food allergy using a “mixed allergen composition” made from 2 to 20 (claim 1) or 6 to 20 (claim 18) allergen-containing flours/powders. The claims are anchored on (i) equal parts by protein weight across multiple flours/powders, (ii) defined allergen sourcing lists that include specified nut flours and specified animal powders, and (iii) dosing frequency at least weekly or at least every other week, with symptom inhibition and optional treatment-supporting timing. The core enforceability risk is that the claim scope is narrow in composition definition (exact allergen species lists + “equal parts by protein weight” + specific dosing cadence) and layered by multiple dependent claims that further restrict dosage form and allergen scope.
H1: US Patent 10,149,904 mixed allergen composition claims for treating food allergies in the US
What are the independent claims (1 and 18) of US Patent 10,149,904?
Claim 1 (broadest structure within the set)
Claim 1 recites a method treating one or more food allergies by administering:
- A mixed allergen composition comprising 2 to 20 different flours or powders.
- At least one nut flour selected from: peanut, almond, walnut, cashew, hazelnut, pecan, pistachio.
- At least one animal powder selected from: shrimp, cod, salmon.
- The composition uses equal parts by protein weight of each flour or powder.
- Administration occurs at least weekly or at least every other week.
The claim also allows typical method-validating features via dependent claims: symptom inhibition (claim 7), treatment duration/timing (claim 2), and patient population and delivery formats (claims 8-10, 11-13, 16).
Claim 18 (second independent, “oral mixed allergen unit composition”)
Claim 18 shifts to an orally administered unit composition with:
- 6 to 20 different flours or powders.
- Nut flour list is the same as claim 1.
- Animal powder list expands to include shrimp, cod, salmon, milk, and egg.
- Non-nut plant flour list includes wheat, sesame, and oat.
- Equal parts by protein weight across each flour/powder.
- It is a unit composition and the method is explicitly oral.
Practical claim geometry
- Equal parts by protein weight is the principal technical limiter. Any competitor design that departs meaningfully from protein-weight equality can be positioned outside literal infringement, unless the competitor still meets the claim’s “equal parts by protein weight” requirement by measurement and formulation.
- The defined allergen species lists restrict what can be combined while still falling within the claim. Adding other allergens outside the lists (or replacing listed allergens with unlisted ones) creates design-around paths.
What dependent claims add scope, and which features are most limiting?
Treatment timing and efficacy qualifiers
- Claim 2: adds “allowing sufficient time” for symptom inhibition.
- Claim 7: requires “significant” symptom inhibition compared to a composition with only one flour/powder.
- This creates an evidentiary and claim-construction pressure point: “significantly” and the comparator baseline (“only one flour or powder”) can be framed narrowly in litigation.
Allergy breadth: single vs multiple
- Claim 3: single food allergy.
- Claim 4: multiple food allergy.
This provides flexibility without expanding the composition definition.
Alloying additional allergens beyond the minimum sets
- Claim 5 expands the permissible flours/powders to each being selected from: shellfish, peanut, tree nut, fish, milk, egg, legume, grain, sesame, and fruit.
- Claim 6 gives a more explicit list: cashew, pistachio, walnut, almond, pecan, chicken egg, cow milk, peanut, shrimp, salmon, wheat, cod, crab, legume, and seed.
These two dependent claims broaden the range of possible included allergen categories, but they still remain tethered to the lists. That structure can support partial enforcement even if a competitor includes fewer allergen types, so long as at least one nut flour and at least one animal powder from the independent claim minimum sets are present and protein-weight equality holds.
Patient population and administration route
- Claim 8 pediatric subject.
- Claim 9 adult subject.
- Claim 10 administration route includes oral, nasal, topical, or subcutaneous.
- Claim 17 specifically requires the composition is administered orally (but that depends on claim 10).
Route flexibility in claim 10 expands potential infringement theories for non-oral formulations that still meet the composition constraints.
Product format and dietary form
- Claim 11: food product.
- Claim 12: baked food product.
This is a strong commercial relevance hook: it targets consumer-like formats that may be easier to distribute and may reduce formulation ambiguity around excipients.
Additional plant and ingredient qualifiers
- Claim 13: at least one non-nut plant flour selected from wheat, sesame, oat.
- Claim 14: at least one powdered hen’s egg.
- Claim 15: soy.
Additive components
- Claim 16: composition comprises vitamin D.
This can narrow infringement for formulations without vitamin D, but it also provides a hook for competitors that use vitamin D as a formulation or nutritional additive.
How do the protein-equal parts limitation and dosing cadence shape infringement risk?
“Equal parts by protein weight of each flour or powder”
This is the linchpin limitation.
- The claim is not framed as equal mass of powders, equal allergen units, or equal weight percentage. It is equal by protein weight.
- Protein assays and allergen extraction methodology become central to literal infringement. In disputes, claim construction can focus on what “protein weight” means in a mixed flour/powder context and whether measurement accounts for varying protein content across source materials.
- From a design-around perspective: a competitor can target deviations such as weighting nut flour and fish/shrimp components differently by protein content, while still using multiple flours/powders that include the same allergen species lists.
Administration frequency: at least weekly or at least every other week
This is not a one-time dosing claim.
- Competitors using less frequent dosing regimens, or dosing every 3-4 weeks (even with similar composition), can seek non-infringement positions tied to cadence.
- Competitors can also seek to distinguish between “unit administration” and intermittent rescue or ad hoc dosing.
What patents protect the same concept around mixed allergen oral immunotherapy?
No numbered “citation set” is provided in the prompt, and no patent bibliographic data is supplied (filing date, assignee, priority, related families, or prosecution history). Without those, a complete and accurate mapping of the broader US patent landscape across earlier priority documents cannot be produced.
What can be stated from the claim text itself is the likely competitive patent “neighborhood” these claims target:
- Food allergy desensitization and immunotherapy methods.
- Multi-allergen approaches (mixing more than one allergen source).
- Oral and/or baked food delivery formats.
- Allergen dosing schedules designed for repeated administration.
- Formulation methods defining how allergen proteins are blended and dosed.
A comprehensive landscape would typically require searching for families that cover:
- multi-allergen compositions,
- baked or food-product allergen delivery,
- specific nut + fish/shellfish combinations,
- and protein-based dosing normalization.
This prompt does not provide enough identifying information to produce that landscape with precision.
When does US Patent 10,149,904 lose exclusivity in the US, and how does timing affect Paragraph IV risk?
No filing, priority, or term-extension data is provided in the prompt; therefore the actual expiration date and any PTA/PTE adjustments cannot be stated accurately. A reliable analysis of Paragraph IV timing also requires identifying the Orange Book–listed reference product (or confirming no listing), plus any relevant Hatch-Waxman or 505(b)(2) pathway links. The prompt does not provide the FDA product identity tied to this patent.
Accordingly, a complete exclusivity and generic entry timeline cannot be generated from the information given.
What is the Orange Book status of US Patent 10,149,904?
No Orange Book listing details are provided (drug name, NDA/BLA, patent listing number, expiration date, or use code). Without that, a factual Orange Book status analysis cannot be completed.
How strong is the patent estate implied by these claims for enforcement in US litigation?
Strength factors
- The claims are highly specific in composition identity: defined allergen lists (nuts and animal powders) and “equal parts by protein weight.”
- Specific dosing frequency (“at least weekly or at least every other week”) is another technical limiter that can align with actual commercial protocols.
- The structure supports enforcement against products that:
- contain multiple flours/powders from the specified lists,
- are blended to equal protein weights,
- and are administered on at least a weekly or biweekly schedule.
Vulnerability factors
- “Equal parts by protein weight” introduces analytical complexity. Competitors can challenge measurement methods or formulation characterization.
- The allergen lists create design-around space: a competitor may swap out one required allergen species (e.g., use a different fish protein source not covered, or omit an animal powder species from the required minimum) or include a nut outside the list.
- Claim 7’s “significant” comparator requirement can be difficult and may invite arguments about statistical thresholds, study design, and baseline comparator adequacy.
- Dependent claims that add vitamin D, food product form, baked format, or specific plant flours narrow additional infringement routes.
Net: enforceability can be meaningful against close embodiments, but the patent is unlikely to be a “broad multi-allergen basket” covering all multi-allergen approaches.
What generic entry risks exist for food allergy immunotherapy under this patent?
Food allergy treatments often involve biologic-like manufacturing complexity rather than standard generic chemistry. The practical “generic risk” under this patent depends on:
- whether a competitor uses the same fixed multi-allergen blend,
- whether it matches the protein-equal blend condition,
- and whether it adheres to the weekly/biweekly dosing cadence.
Without the associated FDA product or pathway identity, the entry-risk assessment cannot be made with factual grounding.
Which competitor strategies are most likely to avoid these claims?
Even without knowing the assignee or prosecution record, the claim text supports the following design-around strategies:
-
Protein-weight non-equality
Formulate mixtures where included flours/powders are not equal by protein weight.
-
Break the minimum allergen sets
Omit one of the required categories from the independent claim minimum:
- remove nut flour species from the required nut list; or
- remove animal powder species from the independent claim animal list (for claim 1: shrimp/cod/salmon only; claim 18 allows a broader animal list but still within its specified set).
-
Change dosing cadence
Administer on a schedule less frequent than weekly/biweekly.
-
Alter delivery route while staying compliant
Because claim 10 covers oral, nasal, topical, subcutaneous, changing route alone is unlikely to avoid claim 1 unless another required limitation is also altered. But changing route can still matter for claim 18, which is oral-specific.
-
Avoid specified food product formats for dependent claims
Avoid baked food product formats if asserting only via claims 11-12.
These are claim-structure-based. The ability to implement them in a clinically effective protocol is a separate business question.
How does claim 18 change scope versus claim 1 for oral-only products?
Claim 18 is more restrictive than claim 1:
- It requires oral administration and a unit composition.
- It requires 6 to 20 flours/powders (not 2 to 20).
- It expands animal powders to include milk and egg but does not remove the requirement that included allergen powders come from its defined sets.
- It includes explicit non-nut plant flour list (wheat, sesame, oat).
So for a competitor:
- a close match to claim 1 might still be outside claim 18 if the product is not “unit” oral, or if the number of components is <6, or if the included plant/animal types fall outside the claim 18 lists.
Key Takeaways
- US Patent 10,149,904 claims a multi-allergen food allergy treatment method built around a defined mixed allergen composition using equal parts by protein weight and weekly/biweekly dosing.
- Independent claims 1 and 18 differ mainly in minimum component count (2 vs 6), animal powder list scope (narrower in claim 1), and route/unit constraints (claim 18 is oral unit composition).
- The enforceability profile is highly dependent on analytical/formulation facts (protein-weight equality) and clinical protocol facts (dosing cadence and symptom inhibition evidence).
- Without the patent’s bibliographic and FDA product linkage data, expiration timing, Orange Book status, and Paragraph IV risk cannot be accurately stated from the provided prompt alone.
FAQs
- What does “equal parts by protein weight” mean in a mixed flour/powder allergen composition?
- If a formulation includes all required allergen species but doses less frequently than every other week, does it avoid claim 1?
- How do claim 11-12 (food product; baked food product) affect enforcement strategy for non-baked formats?
- Does adding vitamin D automatically implicate claim 16, or can it be a dependent-only narrowing feature?
- How would altering the number of allergen powders from 2-5 to 6-20 shift exposure under claim 1 versus claim 18?
References
- US Patent 10,149,904 (claims provided in prompt).
More… ↓
⤷ Start Trial
|
